PHILIP LANDRY: Open Payments
NPI 1639218738 · OPELOUSAS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$416 in 20 payments from 10 companies in 2025. Trend: 2023 $73 · 2024 $58 · 2025 $416
Food & beverage: $416
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Corium, LLC | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $35 |
| HARMONY BIOSCIENCES LLC | 1 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $15 |
Products named: VRAYLAR, TRINTELLIX, Azstarys, CAPLYTA, WAKIX, COBENFY, UZEDY, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
